Orli Even-Or
Director of Biology
Claimed by owner Moya Bio
Former names:
Tumor Immune Conditioning Agents
Moya Bio
About
Moya Bio is developing a novel class of tumor immune conditioning agents. The company's inhibitors of the FAT10 pathway are designed to increase the impact of immunotherapy by sensitizing the tumor to immune-mediated cytotoxicity, to benefit additional patient populations. Moya Bio's translational data demonstrates a correlation between FAT10 down regulation, increased T-cell infiltration into the tumor microenvironment, and inhibition of tumor growth.
The molecular mechanism underlying Moya's FAT10 inhibition platform supports a synergistic effect with immune checkpoint inhibitors, which is expected to enhance their clinical efficacy.
The molecular mechanism underlying Moya's FAT10 inhibition platform supports a synergistic effect with immune checkpoint inhibitors, which is expected to enhance their clinical efficacy.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
Global
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
1
Investors
2
News
(0)The Team
(3)
OE
IM
Inbal Michailovici
Director of Business Development
YMP
Yifat Merbl, PhD
Inventor
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
Undisclosed
Jan 2019
2 Investors
Undisclosed
Others
Academic Techonology
Dec 2017
undefined
Developing a pipeline of modulators of the FAT10 regulatory pathway for cancer treatment
Media gallery
(0)Locations
Israel
Ilan Ramon Street 2, Ness Ziona, Israel
Locations
Israel
Ilan Ramon Street 2, Ness Ziona, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,